Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An unicenter, open-label, 1-arm, 8-week study to evaluate the efficacy, safety and tolerability of ORY-2001 in aggression in adult population with Alzheimer's Disease (AD), Lewy Body Dementia (LBD), Adult attention Deficit Hyperactivity Disorder (ADHD) Borderline Personality Disorder (BPD), Autism Spectrum Disorder (ASD)

Trial Profile

An unicenter, open-label, 1-arm, 8-week study to evaluate the efficacy, safety and tolerability of ORY-2001 in aggression in adult population with Alzheimer's Disease (AD), Lewy Body Dementia (LBD), Adult attention Deficit Hyperactivity Disorder (ADHD) Borderline Personality Disorder (BPD), Autism Spectrum Disorder (ASD)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Oct 2018

At a glance

  • Drugs Vafidemstat (Primary)
  • Indications Aggression
  • Focus Adverse reactions
  • Acronyms REIMAGINE
  • Sponsors Oryzon
  • Most Recent Events

    • 22 Oct 2018 According to an Oryzon media release, a written communication using transcription phenotypes to utilise in this trial methodology will be presented at the Clinical Trials: Methodology session in the 11th Clinical Trials on Alzheimer's Disease international conference, CTAD-2018.
    • 09 Oct 2018 According to an Oryzon media release, first patient has been enrolled in this trial. Dr. Jose Antonio Ramos-Quiroga (head of the Psychiatry Service of the Valle-Hebron hospital) is the principal investigator of this trial.
    • 17 Sep 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top